S. Krishna Padmanabhan

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

Karen A. Tourian, S. Krishna Padmanabhan, James Groark et al. · Clinical Therapeutics · 2009 · 68 citations

Psychiatry, Psychotropic Medication, Phase Iii +9

A Simulation Study to Compare New Adaptive Dose–Ranging Designs

Vladimir Dragalin, Björn Bornkamp, Frank Bretz et al. · Statistics in Biopharmaceutical Research · 2010 · 66 citations

Engineering, Measurement, Optimal Experimental Design +21

Adaptive Designs for Dose-Finding Studies Based on Sigmoid<i>E</i>_maxModel

Vladimir Dragalin, Francis Hsuan, S. Krishna Padmanabhan · Journal of Biopharmaceutical Statistics · 2007 · 55 citations

Pharmacokinetic Modeling, Adaptive Procedure, Uncertainty Quantification +12

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

Alan D. Feiger, Karen A. Tourian, Gregory R. Rosas et al. · CNS Spectrums · 2009 · 45 citations

Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies

José Paulo Pinheiro, Frederic L. Sax, Zoran Antonijevic et al. · Statistics in Biopharmaceutical Research · 2010 · 43 citations

Model-based Dose-ranging Trials, White Paper, Pharmacotherapy +22